Close Menu
November 05, 2020
Sponsored by
Roche

Beyond Traditional Biopsy for Esophageal Cancer: Novel Sampling Methods to Improve Patient Care

GenomeWebinar

Professor of Cancer Prevention,
Hutchison-MRC Research Centre, University of Cambridge

This webinar will provide an overview of novel proximal and distal sampling methods that have promise to improve patient outcomes from esophageal cancer.

Esophageal cancer is a global public health concern due to late presentation and poor patient outcomes. Esophageal adenocarcinoma has increased six-fold over the past 30 years in the UK, northwest Europe, Australia, and North America and it is generally preceded by a premalignant condition called Barrett’s esophagus.

In this webinar, Rebecca Fitzgerald of the Hutchison-MRC Research Center at the University of Cambridge, will discuss two non-endoscopic methods that show promise for improving patient care.

The first method relates to earlier diagnosis. Traditional diagnosis relies on endoscopy for those patients presenting with persistent heartburn unresponsive to medication, or alarm symptoms such as weight loss and dysphagia. Non-endoscopic methods that are affordable, acceptable, and easy to provide in the primary care setting could improve early detection. The Cytosponge-TFF3 test, combines a minimally invasive cell sampling device with immunohistochemical staining for the biomarker trefoil factor 3. The approach is a promising non-endoscopic method with substantial evidence to underpin its use, and Dr. Fitzgerald will present data from the recent randomized controlled trial BEST3.

For those patients diagnosed with invasive adenocarcinoma, earlier detection of relapse and indicators of response to therapy would help to tailor treatment. Blood biopsy to detect circulating tumor DNA is one such approach and Dr. Fitzgerald will present data to show the potential of a ctDNA mutation panel to detect relapse post-surgery in patients with esophageal adenocarcinoma in a retrospective study.

Sponsored by

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.

Sep
23
Sponsored by
Beckman Coulter

This webinar will discuss a streamlined library preparation method for next-generation sequencing (NGS) that improves quality control testing capability while reducing the total number of steps compared to conventional multiplexed library workflows.

Sep
24
Sponsored by
ArcherDX

NTRK fusions are oncogenic drivers in a variety of tumors.

Oct
08
Sponsored by
Genecentric

This webinar, Part 3 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss novel and emerging applications of RNA-based genomic analysis in precision oncology, form characterizing the tumor microenvironment to informing the development of immuno-oncology treatments.

Oct
14
Sponsored by
Inivata

Circulating tumor DNA (ctDNA) can allow clinicians and researchers to better understand which patients are at high risk of recurrence and should be offered intensified chemotherapy or selected for clinical trials.